Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | TLR2 | O60603 | 2/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
| ▸ | MDM4 | O15151 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | MDM2 | Q00987 | 4/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17919592 | 0.90 | KMT2A (0.61) | KMT2ATLR2MDM4TP53MDM2 | |
| SCHEMBL13495919 | 0.90 | KMT2A (0.61) | KMT2ATLR2MDM4TP53MDM2 | |
| SCHEMBL13225950 | 0.89 | TLR2 (0.49) | KMT2ATLR2MDM4TP53MDM2 | |
| SCHEMBL13452073 | 0.88 | TLR2 (0.58) | KMT2ATLR2HDAC1HDAC2MDM4 | |
| SCHEMBL19423731 | 0.88 | TLR2 (0.58) | KMT2ATLR2HDAC1HDAC2MDM4 | |
| SCHEMBL29385146 | 0.88 | TLR2 (0.58) | KMT2ATLR2HDAC1HDAC2MDM4 | |
| SCHEMBL30265401 | 0.87 | KMT2A (0.53) | KMT2ATLR2MDM2 | |
| SCHEMBL29740494 | 0.87 | TLR2 (0.46) | KMT2ATLR2HDAC1HDAC2MDM4 | |
| Hydrochloric Acid SCHEMBL29784769 | 0.87 | TLR2 (0.59) | KMT2ATLR2HDAC1HDAC2MDM4 | |
| SCHEMBL30191436 | 0.86 | KMT2A (0.56) | KMT2ATLR2MDM4TP53MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170037184-A1 | VITAMIN E-BASED NANOCARRIERS FOR DRUG DELIVERY AND METHODS OF MAKING AND USING THE SAME | TAN, CHALET | 2017-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170037184-A1 | VITAMIN E-BASED NANOCARRIERS FOR DRUG DELIVERY AND METHODS OF MAKING AND USING THE SAME | TTPA, ABCE1, VDR | KMT2A 4245/4885TLR2 2132/4885HDAC1 4350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.